Journal of Clinical and Diagnostic Research, ISSN - 0973 - 709X

Users Online : 24947

AbstractMaterial and MethodsResultsDiscussionConclusionReferences
Article in PDF How to Cite Citation Manager Readers' Comments (0) Audio Visual Article Statistics Link to PUBMED Print this Article Send to a Friend
Advertisers Access Statistics Resources

Dr Mohan Z Mani

"Thank you very much for having published my article in record time.I would like to compliment you and your entire staff for your promptness, courtesy, and willingness to be customer friendly, which is quite unusual.I was given your reference by a colleague in pathology,and was able to directly phone your editorial office for clarifications.I would particularly like to thank the publication managers and the Assistant Editor who were following up my article. I would also like to thank you for adjusting the money I paid initially into payment for my modified article,and refunding the balance.
I wish all success to your journal and look forward to sending you any suitable similar article in future"

Dr Mohan Z Mani,
Professor & Head,
Department of Dermatolgy,
Believers Church Medical College,
Thiruvalla, Kerala
On Sep 2018

Prof. Somashekhar Nimbalkar

"Over the last few years, we have published our research regularly in Journal of Clinical and Diagnostic Research. Having published in more than 20 high impact journals over the last five years including several high impact ones and reviewing articles for even more journals across my fields of interest, we value our published work in JCDR for their high standards in publishing scientific articles. The ease of submission, the rapid reviews in under a month, the high quality of their reviewers and keen attention to the final process of proofs and publication, ensure that there are no mistakes in the final article. We have been asked clarifications on several occasions and have been happy to provide them and it exemplifies the commitment to quality of the team at JCDR."

Prof. Somashekhar Nimbalkar
Head, Department of Pediatrics, Pramukhswami Medical College, Karamsad
Chairman, Research Group, Charutar Arogya Mandal, Karamsad
National Joint Coordinator - Advanced IAP NNF NRP Program
Ex-Member, Governing Body, National Neonatology Forum, New Delhi
Ex-President - National Neonatology Forum Gujarat State Chapter
Department of Pediatrics, Pramukhswami Medical College, Karamsad, Anand, Gujarat.
On Sep 2018

Dr. Kalyani R

"Journal of Clinical and Diagnostic Research is at present a well-known Indian originated scientific journal which started with a humble beginning. I have been associated with this journal since many years. I appreciate the Editor, Dr. Hemant Jain, for his constant effort in bringing up this journal to the present status right from the scratch. The journal is multidisciplinary. It encourages in publishing the scientific articles from postgraduates and also the beginners who start their career. At the same time the journal also caters for the high quality articles from specialty and super-specialty researchers. Hence it provides a platform for the scientist and researchers to publish. The other aspect of it is, the readers get the information regarding the most recent developments in science which can be used for teaching, research, treating patients and to some extent take preventive measures against certain diseases. The journal is contributing immensely to the society at national and international level."

Dr Kalyani R
Professor and Head
Department of Pathology
Sri Devaraj Urs Medical College
Sri Devaraj Urs Academy of Higher Education and Research , Kolar, Karnataka
On Sep 2018

Dr. Saumya Navit

"As a peer-reviewed journal, the Journal of Clinical and Diagnostic Research provides an opportunity to researchers, scientists and budding professionals to explore the developments in the field of medicine and dentistry and their varied specialities, thus extending our view on biological diversities of living species in relation to medicine.
ĎKnowledge is treasure of a wise man.í The free access of this journal provides an immense scope of learning for the both the old and the young in field of medicine and dentistry as well. The multidisciplinary nature of the journal makes it a better platform to absorb all that is being researched and developed. The publication process is systematic and professional. Online submission, publication and peer reviewing makes it a user-friendly journal.
As an experienced dentist and an academician, I proudly recommend this journal to the dental fraternity as a good quality open access platform for rapid communication of their cutting-edge research progress and discovery.
I wish JCDR a great success and I hope that journal will soar higher with the passing time."

Dr Saumya Navit
Professor and Head
Department of Pediatric Dentistry
Saraswati Dental College
On Sep 2018

Dr. Arunava Biswas

"My sincere attachment with JCDR as an author as well as reviewer is a learning experience . Their systematic approach in publication of article in various categories is really praiseworthy.
Their prompt and timely response to review's query and the manner in which they have set the reviewing process helps in extracting the best possible scientific writings for publication.
It's a honour and pride to be a part of the JCDR team. My very best wishes to JCDR and hope it will sparkle up above the sky as a high indexed journal in near future."

Dr. Arunava Biswas
MD, DM (Clinical Pharmacology)
Assistant Professor
Department of Pharmacology
Calcutta National Medical College & Hospital , Kolkata

Dr. C.S. Ramesh Babu
" Journal of Clinical and Diagnostic Research (JCDR) is a multi-specialty medical and dental journal publishing high quality research articles in almost all branches of medicine. The quality of printing of figures and tables is excellent and comparable to any International journal. An added advantage is nominal publication charges and monthly issue of the journal and more chances of an article being accepted for publication. Moreover being a multi-specialty journal an article concerning a particular specialty has a wider reach of readers of other related specialties also. As an author and reviewer for several years I find this Journal most suitable and highly recommend this Journal."
Best regards,
C.S. Ramesh Babu,
Associate Professor of Anatomy,
Muzaffarnagar Medical College,
On Aug 2018

Dr. Arundhathi. S
"Journal of Clinical and Diagnostic Research (JCDR) is a reputed peer reviewed journal and is constantly involved in publishing high quality research articles related to medicine. Its been a great pleasure to be associated with this esteemed journal as a reviewer and as an author for a couple of years. The editorial board consists of many dedicated and reputed experts as its members and they are doing an appreciable work in guiding budding researchers. JCDR is doing a commendable job in scientific research by promoting excellent quality research & review articles and case reports & series. The reviewers provide appropriate suggestions that improve the quality of articles. I strongly recommend my fraternity to encourage JCDR by contributing their valuable research work in this widely accepted, user friendly journal. I hope my collaboration with JCDR will continue for a long time".

Dr. Arundhathi. S
MBBS, MD (Pathology),
Sanjay Gandhi institute of trauma and orthopedics,
On Aug 2018

Dr. Mamta Gupta,
"It gives me great pleasure to be associated with JCDR, since last 2-3 years. Since then I have authored, co-authored and reviewed about 25 articles in JCDR. I thank JCDR for giving me an opportunity to improve my own skills as an author and a reviewer.
It 's a multispecialty journal, publishing high quality articles. It gives a platform to the authors to publish their research work which can be available for everyone across the globe to read. The best thing about JCDR is that the full articles of all medical specialties are available as pdf/html for reading free of cost or without institutional subscription, which is not there for other journals. For those who have problem in writing manuscript or do statistical work, JCDR comes for their rescue.
The journal has a monthly publication and the articles are published quite fast. In time compared to other journals. The on-line first publication is also a great advantage and facility to review one's own articles before going to print. The response to any query and permission if required, is quite fast; this is quite commendable. I have a very good experience about seeking quick permission for quoting a photograph (Fig.) from a JCDR article for my chapter authored in an E book. I never thought it would be so easy. No hassles.
Reviewing articles is no less a pain staking process and requires in depth perception, knowledge about the topic for review. It requires time and concentration, yet I enjoy doing it. The JCDR website especially for the reviewers is quite user friendly. My suggestions for improving the journal is, more strict review process, so that only high quality articles are published. I find a a good number of articles in Obst. Gynae, hence, a new journal for this specialty titled JCDR-OG can be started. May be a bimonthly or quarterly publication to begin with. Only selected articles should find a place in it.
An yearly reward for the best article authored can also incentivize the authors. Though the process of finding the best article will be not be very easy. I do not know how reviewing process can be improved. If an article is being reviewed by two reviewers, then opinion of one can be communicated to the other or the final opinion of the editor can be communicated to the reviewer if requested for. This will help oneís reviewing skills.
My best wishes to Dr. Hemant Jain and all the editorial staff of JCDR for their untiring efforts to bring out this journal. I strongly recommend medical fraternity to publish their valuable research work in this esteemed journal, JCDR".

Dr. Mamta Gupta
(Ex HOD Obs &Gynae, Hindu Rao Hospital and associated NDMC Medical College, Delhi)
Aug 2018

Dr. Rajendra Kumar Ghritlaharey

"I wish to thank Dr. Hemant Jain, Editor-in-Chief Journal of Clinical and Diagnostic Research (JCDR), for asking me to write up few words.
Writing is the representation of language in a textual medium i e; into the words and sentences on paper. Quality medical manuscript writing in particular, demands not only a high-quality research, but also requires accurate and concise communication of findings and conclusions, with adherence to particular journal guidelines. In medical field whether working in teaching, private, or in corporate institution, everyone wants to excel in his / her own field and get recognised by making manuscripts publication.

Authors are the souls of any journal, and deserve much respect. To publish a journal manuscripts are needed from authors. Authors have a great responsibility for producing facts of their work in terms of number and results truthfully and an individual honesty is expected from authors in this regards. Both ways its true "No authors-No manuscripts-No journals" and "No journalsĖNo manuscriptsĖNo authors". Reviewing a manuscript is also a very responsible and important task of any peer-reviewed journal and to be taken seriously. It needs knowledge on the subject, sincerity, honesty and determination. Although the process of reviewing a manuscript is a time consuming task butit is expected to give one's best remarks within the time frame of the journal.
Salient features of the JCDR: It is a biomedical, multidisciplinary (including all medical and dental specialities), e-journal, with wide scope and extensive author support. At the same time, a free text of manuscript is available in HTML and PDF format. There is fast growing authorship and readership with JCDR as this can be judged by the number of articles published in it i e; in Feb 2007 of its first issue, it contained 5 articles only, and now in its recent volume published in April 2011, it contained 67 manuscripts. This e-journal is fulfilling the commitments and objectives sincerely, (as stated by Editor-in-chief in his preface to first edition) i e; to encourage physicians through the internet, especially from the developing countries who witness a spectrum of disease and acquire a wealth of knowledge to publish their experiences to benefit the medical community in patients care. I also feel that many of us have work of substance, newer ideas, adequate clinical materials but poor in medical writing and hesitation to submit the work and need help. JCDR provides authors help in this regards.
Timely publication of journal: Publication of manuscripts and bringing out the issue in time is one of the positive aspects of JCDR and is possible with strong support team in terms of peer reviewers, proof reading, language check, computer operators, etc. This is one of the great reasons for authors to submit their work with JCDR. Another best part of JCDR is "Online first Publications" facilities available for the authors. This facility not only provides the prompt publications of the manuscripts but at the same time also early availability of the manuscripts for the readers.
Indexation and online availability: Indexation transforms the journal in some sense from its local ownership to the worldwide professional community and to the public.JCDR is indexed with Embase & EMbiology, Google Scholar, Index Copernicus, Chemical Abstracts Service, Journal seek Database, Indian Science Abstracts, to name few of them. Manuscriptspublished in JCDR are available on major search engines ie; google, yahoo, msn.
In the era of fast growing newer technologies, and in computer and internet friendly environment the manuscripts preparation, submission, review, revision, etc and all can be done and checked with a click from all corer of the world, at any time. Of course there is always a scope for improvement in every field and none is perfect. To progress, one needs to identify the areas of one's weakness and to strengthen them.
It is well said that "happy beginning is half done" and it fits perfectly with JCDR. It has grown considerably and I feel it has already grown up from its infancy to adolescence, achieving the status of standard online e-journal form Indian continent since its inception in Feb 2007. This had been made possible due to the efforts and the hard work put in it. The way the JCDR is improving with every new volume, with good quality original manuscripts, makes it a quality journal for readers. I must thank and congratulate Dr Hemant Jain, Editor-in-Chief JCDR and his team for their sincere efforts, dedication, and determination for making JCDR a fast growing journal.
Every one of us: authors, reviewers, editors, and publisher are responsible for enhancing the stature of the journal. I wish for a great success for JCDR."

Thanking you
With sincere regards
Dr. Rajendra Kumar Ghritlaharey, M.S., M. Ch., FAIS
Associate Professor,
Department of Paediatric Surgery, Gandhi Medical College & Associated
Kamla Nehru & Hamidia Hospitals Bhopal, Madhya Pradesh 462 001 (India)
On May 11,2011

Dr. Shankar P.R.

"On looking back through my Gmail archives after being requested by the journal to write a short editorial about my experiences of publishing with the Journal of Clinical and Diagnostic Research (JCDR), I came across an e-mail from Dr. Hemant Jain, Editor, in March 2007, which introduced the new electronic journal. The main features of the journal which were outlined in the e-mail were extensive author support, cash rewards, the peer review process, and other salient features of the journal.
Over a span of over four years, we (I and my colleagues) have published around 25 articles in the journal. In this editorial, I plan to briefly discuss my experiences of publishing with JCDR and the strengths of the journal and to finally address the areas for improvement.
My experiences of publishing with JCDR: Overall, my experiences of publishing withJCDR have been positive. The best point about the journal is that it responds to queries from the author. This may seem to be simple and not too much to ask for, but unfortunately, many journals in the subcontinent and from many developing countries do not respond or they respond with a long delay to the queries from the authors 1. The reasons could be many, including lack of optimal secretarial and other support. Another problem with many journals is the slowness of the review process. Editorial processing and peer review can take anywhere between a year to two years with some journals. Also, some journals do not keep the contributors informed about the progress of the review process. Due to the long review process, the articles can lose their relevance and topicality. A major benefit with JCDR is the timeliness and promptness of its response. In Dr Jain's e-mail which was sent to me in 2007, before the introduction of the Pre-publishing system, he had stated that he had received my submission and that he would get back to me within seven days and he did!
Most of the manuscripts are published within 3 to 4 months of their submission if they are found to be suitable after the review process. JCDR is published bimonthly and the accepted articles were usually published in the next issue. Recently, due to the increased volume of the submissions, the review process has become slower and it ?? Section can take from 4 to 6 months for the articles to be reviewed. The journal has an extensive author support system and it has recently introduced a paid expedited review process. The journal also mentions the average time for processing the manuscript under different submission systems - regular submission and expedited review.
Strengths of the journal: The journal has an online first facility in which the accepted manuscripts may be published on the website before being included in a regular issue of the journal. This cuts down the time between their acceptance and the publication. The journal is indexed in many databases, though not in PubMed. The editorial board should now take steps to index the journal in PubMed. The journal has a system of notifying readers through e-mail when a new issue is released. Also, the articles are available in both the HTML and the PDF formats. I especially like the new and colorful page format of the journal. Also, the access statistics of the articles are available. The prepublication and the manuscript tracking system are also helpful for the authors.
Areas for improvement: In certain cases, I felt that the peer review process of the manuscripts was not up to international standards and that it should be strengthened. Also, the number of manuscripts in an issue is high and it may be difficult for readers to go through all of them. The journal can consider tightening of the peer review process and increasing the quality standards for the acceptance of the manuscripts. I faced occasional problems with the online manuscript submission (Pre-publishing) system, which have to be addressed.
Overall, the publishing process with JCDR has been smooth, quick and relatively hassle free and I can recommend other authors to consider the journal as an outlet for their work."

Dr. P. Ravi Shankar
KIST Medical College, P.O. Box 14142, Kathmandu, Nepal.
On April 2011

Dear team JCDR, I would like to thank you for the very professional and polite service provided by everyone at JCDR. While i have been in the field of writing and editing for sometime, this has been my first attempt in publishing a scientific paper.Thank you for hand-holding me through the process.

Dr. Anuradha
On Jan 2020

Important Notice

Original article / research
Year : 2008 | Month : August | Volume : 2 | Issue : 4 | Page : 946 - 951 Full Version

A Comparative Clinical Study of the Docetaxel-Carboplatin combination and the Gemcitabine- Carboplatin combination in Patients with Non Small Cell Lung Cancer

Published: August 1, 2008 | DOI:

** &**** Department of Pharmacology,Visveswarapura Institute of Pharmaceutical Sciences,Banshankari IInd stage, Bangalore-560070(India)*** Medical Head,Curie centre of Oncology,St. Johns Medical college campus, Koramangala,Bangalore-560044 (India)

Correspondence Address :
Sumanth M Department of Pharmacology, Visveswarapura Institute of
Pharmaceutical Sciences,
Banshankari IInd stage, Bangalore-560070 (India)


Back Ground: Non small cell lung cancer (NSCLC) constitutes about 75-80% of all lung cancer cases. In the chemotherapy of NSCLC, a platinum drug can be combined with taxanes or Gemcitabine.
Aim: To compare the Docetaxel-Carboplatin (DC) and Gemcitabine-Carboplatin (GC) treatment regimen in patients with NSCLC.
Setting And Design: Prospective, Randomized, Open labeled double arm study
Methods: Thirty patients with stage IIIB/IV NSCLC were randomly divided into two groups. The patients of the DC group were treated with Docetaxel (75 mg/m2, day one) and Carboplatin (calculated to give an AUC of 6 mg/ml, day one) and those of the GC group were treated with Gemcitabine (1200 mg/m2, day one and eight) and Carboplatin (day one). Treatment cycles were repeated every 21 days for a period of three cycles. Response and toxicity were assessed using WHO criteria.
Results: The patients in both the groups were well balanced for demographics and disease. Objective responses were similar in the two groups; DC group: 20% partial response, 60% stable disease and 20% of progressive disease. GC group: 33.3% partial response, 53.3% stable disease and 13.3% progressive disease. The only significant toxicity was anemia in the DC group. The evaluation of the quality of life of patients in both the groups showed significant change in the incidence of anemia, dysphagia and peripheral neuropathy in the DC group. Alopecia was significantly higher among the patients of the GC group.
Conclusion: The toxicity profiles of the Docetaxel-Carboplatin and Gemcitabine- Carboplatin combinations were similar. The Docetaxel-Carboplatin treatment regimen is cost effective for patients. Global quality of health is not improved in either combination, although advantages in some components of ten QOL were apparent.


Non small cell lung cancer (NSCLC), Docetaxel, Gemcitabine, Carboplatin, Quality of life, tumour response, haematology.

Uncontrolled multiplication and spread of abnormal forms of cells within the body is termed as Cancer. It is one of the major causes of death in the developed nations (1). Lung cancer has a death rate, greater than that attributed to colorectal, breast and prostate cancers combined (2).Non small cell lung cancer (NSCLC) constitutes about 75-80% of all lung cancer cases, and accounts for 1.2 million cases world wide each year(3). The role of platinum-based chemotherapy has now been clearly established in advanced stage NSCLC. Chemotherapy improves survival rate in patients with stage IV disease as compared to best supportive care, in patients with inoperable stage III, when combined with thoracic radiation and compared to radiation alone. Chemotherapy improves survival rate in patients with stage IIIA (N2) also, when given before radical surgery as compared to surgery alone (3). One of the chemotherapeutic treatments of NSCLC is, combining a platinum agent with one of the two taxanes (Docetaxel, Paclitaxel), vinorelbine or gemcitabine(4). The possible haematological and non haematological toxicities of these treatments include anemia, neutropenia, thrombocytopenia, nausea/vomiting, mild skin rash, diarrohea, mucositosis, constipation, neurotoxocity, asthenia, neutropenia, fluid retention, asthenia, alopecia, hypersensitivity reactions, and skin and nail toxicities (5),(6).

The assessment of a cancer patient broadly includes two sets of endpoints - cancer outcome and patient outcome. Cancer outcome measures the response of a patient to treatment, duration of response, symptom free period, and early recognition of relapse. Patient outcome, on the other hand, assesses the survival benefit attained after treatment as measured by the increase in life span, and the quality of life before and after therapy. Quality of life (QOL) is a broad, subjective, and multidimensional concept that includes: (a) Physical health and symptoms (b) Functional status and activities of daily living (7). The present study was taken up with the aim of comparing Docetaxel-Carboplatin and Gemcitabine-Carboplatin treatment regimens in patients with non small cell lung cancer.

Material and Methods

A prospective, randomized, open labeled, double-arm study of a total duration of eight months, was taken up from November 2006 to June 2007, at the Curie Centre of Oncology, St. Johns Medical College and Hospital campus, Bangalore. Thirty patients of NSCLC of both sexes with an age range of 35-65 years, from different strata of society, were included in the study. The institutional Ethics Committee¬Āfs permission was obtained before starting the studies.

Inclusion and exclusion criteria
Patients suffering from cytologically or histologically confirmed stage III/IVB non small cell carcinoma, with no prior chemotherapy treatment given, were included in this study. Patients having a WHO performance status of <3 and adequate liver, kidney and bone marrow functions, were included in the study. All patients signed informed consent before enrollment into the study.

Patients with active infection, symptomatic central nervous system metastases, pregnancy, second primary malignancy, or serious concomitant systemic disorders, inadequate liver function (bilirubin >1.5 times upper limit of normal), with alanine transaminase or aspartate transaminase less than three times normal or inadequate renal function, HIV/HbSAg +ve, or with life threatening systemic diseases were excluded from the study.

Treatment Regimen
Hospitalized patients were centrally randomized according to age, performance status and stage of disease to receive either Docetaxel-Carboplatin (DC group) or Gemcitabine-Carboplatin (GC group) treatment. DC group patients received Docetaxel 75 mg/ m2 as a one-hour i.v. infusion, immediately followed by, Carboplatin, calculated to give an AUC of 6 mg.min/ml according to the Calvert formula. The GC group patients received 1200 mg/m2 Gemcitabine intravenously over 30 minutes on days one and eight, and Carboplatin on day one. Standard WHO toxicity and response criteria were used. To access the toxicity during treatment, differential leucocyte count and platelet count were done weekly. In the event of grade three or four neutropenia, febrile neutropenia, or grade four thrombocytopenia, the complete blood-cell count was done daily until the absolute granulocyte count was greater than 1200/∆í√äL and the platelet count was greater than 50¬Ā~103/∆í√äL. A detailed medical history was recorded, and a complete physical examination was done before each course of treatment, to assess symptoms of the disease and treatment toxicity. Biochemical tests, electrocardiogram and chest radiographs were done at the beginning of the Ist course and after completion of the IIIrd course.

The quality of life (QOL) was assessed with the English or Kannada version of EORTC QLQ-C30 and QLQ-LC 13 questionnaires. The patients answered the questionnaire before and during the treatment. QOL scores were assessed according to the EORTC-QLQ scoring manual. The scores were transferred to a scale of 0 to 100. A high score for a functional or global QOL scale represents a relatively high/healthy level of functioning or global quality of life, whereas a high score for a symptom scale represents the presence of a symptom or problem(s).

Statistical Analysis
Values were expressed as mean ¬Ā} SEM or as percentages, and were analyzed using the Fisher exact test. The quality of life questionnaires were analyzed by the Wilcoxon signed rank test.


Demographics of the thirty patients (15 patients each in both the groups) enrolled in the study are shown in (Table/Fig 1), which indicates that incidence of NSCLC is less in females.

As shown in (Table/Fig 2), incidence of anaemia was statistically significant (P=0.065) in patients treated with the DC combination as compared to patients treated with the GC combination. Incidence of neutropenia, leucopenia, nausea/vomiting and alopecia, was higher in patients treated with the GC combination than in those treated with the DC combination, while incidence of thrombocytopenia and diarrohoea was slightly higher in patients treated with DC combination.

As shown in (Table/Fig 3), incidence of partial response and progressive disease was seen more in the GC group, and the incidence of stable disease was more in the DC group. On comparison of the tumour size pre and post chemotherapy, no significant difference was seen between the DC group (P= 0.078) and the GC group (P=0.070)

As shown in (Table/Fig 4)and(Table/Fig 5), the functional scale of patients treated with the DC combination showed a decline in the physical and social functioning, while the patients treated with GC combination showed a decline in role, emotional and cognitive functioning.

When the symptom scales of patients were assessed using the EORTC QLQ-LC13 questionnaire, it was found that incidence of dysphagia and peripheral neuropathy was significantly more in the patients treated with the DC combination. The incidence of alopecia significantly increased in the patients treated with the GC combination as seen in (Table/Fig 6) .


New strategies are required in the treatment of NSCLC for clinically significant progress. The emergence of new generations of chemotherapeutic agents with anticancer activity in NSCLC, has generated interest in the development of platinum based treatment regimens. Various studies have substantiated the combined use of Docetaxel-Carboplatin and Gemcitabine-Carboplatin (8),(9).

The present clinical study indicates a higher incidence of NSCLC in males. This may be due to various reasons like smoking, occupational hazards etc. The toxicity profiles of the DC and GC regimens are similar. Patients treated with the DC regimen showed a higher incidence of anemia, whereas nausea/vomiting was severe in the patients treated with the GC arm. These toxicities may be due to the platinum based drug, Carboplatin, as indicated by a randomized study (10) conducted by some scientist, earlier. It is also reported that carboplatin-based chemotherapy develops the risk of grade 3 or 4 thrombocytopenia, anemia, neutropenia and neurotoxicity (11).

Platinum based chemotherapy regimens are the standard treatment for patients with NSCLC. The present clinical study is the first of its kind, which attempts to assess the QOL of NSCLC patients treated with the GC and DC combination regimens using EORTC guidelines. The results showed that there was no significant improvement in the quality of life of patients treated with either regimen. The incidence of alopecia was significantly increased in the patients treated with the GC regimen, and the incidence of dysphagia and peripheral neuropathy was significant in the patients treated with the DC regimen. There was no significant advantage of either of the treatment arm over the other, but for cost effectiveness.

Cost Effectiveness of the Treatment
The cost of the GC combination treatment regimen for a patient of NSCLC for three treatment cycles is in the range of Rs. 45,500-66,780. The cost of the DC combination treatment regimen for a patient of NSCLC after three treatment cycles is about of Rs. 43,500. It is evident that from the patient¬Āfs point of view, the DC combination treatment regimen is cost effective. Also, it is interesting to note that there is no significant advantage of the gemcitabine treatment over the docetaxel treatment regimen (12).


Both the DC and GC combination regimens are effective in the treatment of NSCLC. The toxicities due to both drug combinations are similar. The global quality of health is not improved by either combination.
From the patient¬Āfs point of view, the DC combination treatment regimen is cost effective.

Limitation of the Study
Because of the short term nature of study, survival rate, time to progressive disease and response duration could not be evaluated. Emphasis was given to the tumour response, toxicity profiles and quality of life of the patients.

Suggestion to Oncologists
Since the toxicity profile of the both the combinations is the same, and the DC combination being cost effective, it may be recommended that the DC (Docetaxel-Carboplatin) combination is a better treatment option as compared to the GC (Gemcitabine-Carboplatin) combination, to treat NSCLC.


Rang HP, Dale MM, Ritter JM, Moore PK. In: Pharmacology, 5th edition, London: Churchill livingstone publications; 2003;50:PP693
O¬Āfbrien MER, Szczesna A, Karnicka H, Zatloukal P, EIsen T, Hartmann W, et. al. Vinorelbine alternating oral and intravaenous plus Carboplatin in advanced non small cell lung cancer: results of a multi centre phase II study. Ann Oncol 2004;15(6):921-7
Tiseo M, Franciosi V, Grossi F and Ardizonni F. Adjuvant chemotherapy for non-small cell lung cancer: Ready for clinical practice? Eur J Cancer 2006; 42(1):8-16.)
Rogerio L. Options in Advanced Non-Small Cell Lung Cancer: A Review and Report on a Phase II Study of Vinorelbine plus Gemcitabine. Oncologist 2001; 6(l 1):16-9.
Evans WK. Rationale for the treatment of NSCLC. Lung Cancer 1993;9:5-14
Pasetto LM, D¬Āfandrea MR, Falci C, Monfardini S. Gemcitabine in advanced biliary tract cancers. Crit Rev Oncol 2007;61(3):230-42
Mohan A, Randeep G, Pathak AK, Manisha B, Pal Hemraj, Mohan C, Quality of life measures in lung cancer. Indian J Pharmacol 2005;42(3):125-32
Barlesi F, Doddoli C, Loundou A, Pillet E, Thomas P, Auquier P. Preoperative psychological global well being index (PGWBI) predicts postoperative quality of life for patients with non-small cell lung cancer managed with thoracic surgery. European Journal of Cardio-Thoracic Surgery 2006;30(3):548-53
Kelly K, Kamel MN, Pan X, Murphy J, Prindiville S and Bunn PA, Jr.A Phase I/II Trial of Paclitaxel, Carboplatin, and Gemcitabine in Untreated Patients with Advanced Non-Small Cell Lung Cancer. Clin Cancer Res 2000;6:3474-79
Georgoulias V, Papadakis E, Alexopoulos A, Tsiafaki X, Rapti A, Veslemes M, Palamidas, et al. Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: A randomized multicentre trial. Lancet 2001; 357(9267):1478-84.
Jiang J, Liang X, Zhou X, Huang R, Chu Z., A meta-analysis of randomized controlled trials comparing carboplatin-based to cisplatin-based chemotherapy in advanced non-small cell lung cancer. Lung Cancer 2007; 57(3):348-58
Leong Swan Swan, Toh, Chee Keong ,Lim, Wan Teck, Lin, Xu Tan, Say Beng , Poon Donald ,Tay Miah Hiang ,Foo Kian Fong , HoJuliana Tan Eng Huat. A Randomized Phase II Trial of Single-Agent Gemcitabine, Vinorelbine, or Docetaxel in Patients with Advanced Non-small Cell Lung Cancer Who Have Poor Performance Status and/or Are Elderly. J. of Thoracic Oncology. 2007; 2(3):230-36

JCDR is now Monthly and more widely Indexed .
  • Emerging Sources Citation Index (Web of Science, thomsonreuters)
  • Index Copernicus ICV 2017: 134.54
  • Academic Search Complete Database
  • Directory of Open Access Journals (DOAJ)
  • Embase
  • EBSCOhost
  • Google Scholar
  • HINARI Access to Research in Health Programme
  • Indian Science Abstracts (ISA)
  • Journal seek Database
  • Google
  • Popline (reproductive health literature)